AXIM Biotechnologies, Inc received positive pharmacokinetic (PK) data results for its CanChew Plus cannabidiol (CBD) Gum, according to a company press release.

CanChew Plus is a non-habit forming, hemp-derived CBD functional chewing gum that is available in all 50 states. Currently, AXIM is gearing up for a clinical trial to prove the efficacy of CBD for the treatment of irritable bowel syndrome (IBS).

The single-dose study for 10 mg and 30 mg of CBD determined the concentration of CBD in the blood after chewing CanChew Plus Gum for 30 minutes in healthy participants.

The results of the study showed the 30 mg dosage as the most favorable, and the data will be used to determine the optimal dosage for patients in the IBS trial, according to the release.

“These results show that excellent bioavailability for CBD may be achieved via our proprietary chewing gum delivery system, so that patients suffering from IBS may have symptomatic relief using an easy-to-use solution,” said George E. Anastassov, MD, DDS, MBA, chief executive officer of AXIM Biotech. “We believe that we can match or improve the bioavailability profile for CBD compared to other delivery systems such as smoking or oral intake. We look forward to entering clinical trial and making available our cannabis-based medicinal solutions to patients suffering from IBS and other gastrointestinal disorders as soon as possible.”